SyntekaBio

SyntekaBio Supply Chain

Supply Chain of SyntekaBio (226330.KQ) as of Nov 20, 2026.

Supply Chain

-

Last updated:

Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.

SyntekaBio Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
5 companies
#NameTrend
1
Kainos Medicine
Supplier·Customer·Biotechnology·KR
-0.18
0.61
-0.13
-0.01
-0.15
0.46
2
GemVax & KAEL
Supplier·Customer·Semiconductors & Semiconductor Equipment·KR
0.38
-0.31
0.52
0.72
-0.01
0.45
3
Legochem Biosciences
Customer·Life Sciences Tools & Services·KR
0.27
0.57
0.86
0.71
0.37
0.44
#NameTrend
1
SCM LIFESCIENCE
Supplier·Customer·Biotechnology·KR
-0.24
0.06
0.85
0.65
0.06
—
2
Cellid
Supplier·Customer·Biotechnology·KR
0.49
0.48
0.88
0.77
0.01
-0.18

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

All Key Metrics — SyntekaBio